Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dipti Pawaskar

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|August 22, 2009
Methods of utilizing baseline values for indirect response modelsSukyung Woo, Dipti Pawaskar, William J Jusko
The Journal of Allergy and Clinical Immunology. in Practice|October 27, 2019
C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary AngioedemaAllen P Kaplan, Dipti Pawaskar, Joseph Chiao
Clinical and Translational Science|December 3, 2021
A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimabAndrew McKenzie, Anthony Roberts, Sourabh Malandkar, et al.
Allergy and Asthma Proceedings|August 16, 2018
Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trialH Henry Li, Sarah Mycroft, Sandra Christiansen, et al.
Journal of Clinical Pharmacology|November 25, 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White AdultsFiona Glassman, John-Philip Lawo, Mihai Alexandru Bica, et al.
Clinical and Translational Science|November 23, 2021
Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312)Dipti Pawaskar, Xi Chen, Fiona Glassman, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 10, 2018
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary AngioedemaYing Zhang, Michael A Tortorici, Dipti Pawaskar, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 13, 2018
Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedemaDipti Pawaskar, Michael A Tortorici, Bruce Zuraw, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
Lancet (London, England)|April 24, 2026
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trialTuan Vu, Ali A Habib, Saiju Jacob, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|August 22, 2009
Methods of utilizing baseline values for indirect response modelsSukyung Woo, Dipti Pawaskar, William J Jusko
The Journal of Allergy and Clinical Immunology. in Practice|October 27, 2019
C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary AngioedemaAllen P Kaplan, Dipti Pawaskar, Joseph Chiao
Clinical and Translational Science|December 3, 2021
A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimabAndrew McKenzie, Anthony Roberts, Sourabh Malandkar, et al.
Allergy and Asthma Proceedings|August 16, 2018
Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trialH Henry Li, Sarah Mycroft, Sandra Christiansen, et al.
Journal of Clinical Pharmacology|November 25, 2024
Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White AdultsFiona Glassman, John-Philip Lawo, Mihai Alexandru Bica, et al.
Clinical and Translational Science|November 23, 2021
Pharmacokinetic/pharmacodynamic modeling for dose selection for the first-in-human trial of the activated Factor XII inhibitor garadacimab (CSL312)Dipti Pawaskar, Xi Chen, Fiona Glassman, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 10, 2018
Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary AngioedemaYing Zhang, Michael A Tortorici, Dipti Pawaskar, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 13, 2018
Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedemaDipti Pawaskar, Michael A Tortorici, Bruce Zuraw, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
Lancet (London, England)|April 24, 2026
Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trialTuan Vu, Ali A Habib, Saiju Jacob, et al.
Pageof 2